See more : Medimaging Integrated Solution Inc. (6796.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Imago BioSciences, Inc. (IMGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imago BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ace Men Engg Works Limited (ACEMEN.BO) Income Statement Analysis – Financial Results
- E for L Aim Public Company Limited (EFORL.BK) Income Statement Analysis – Financial Results
- Tesco PLC (TCO0.DE) Income Statement Analysis – Financial Results
- Epiroc AB (publ) (EPI-A.ST) Income Statement Analysis – Financial Results
- Lypsa Gems & Jewellery Limited (LYPSAGEMS.NS) Income Statement Analysis – Financial Results
Imago BioSciences, Inc. (IMGO)
About Imago BioSciences, Inc.
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.26M | 14.90M | 8.24M |
| General & Administrative | 10.26M | 3.18M | 2.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 10.26M | 3.18M | 2.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.52M | 18.07M | 10.66M |
| Cost & Expenses | 42.52M | 18.07M | 10.66M |
| Interest Income | 314.00K | 48.00K | 38.00K |
| Interest Expense | 314.00K | 48.00K | 38.00K |
| Depreciation & Amortization | 6.00K | 1.00K | -208.00K |
| EBITDA | -42.52M | -17.78M | -10.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.00M | -18.07M | -10.66M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.00K | 242.00K | -246.00K |
| Income Before Tax | -42.31M | -17.83M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | 3.00K | 0.00 |
| Net Income | -42.31M | -17.83M | -10.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -3.16 | -1.33 | -0.81 |
| EPS Diluted | -3.16 | -1.33 | -0.81 |
| Weighted Avg Shares Out | 13.38M | 13.38M | 13.38M |
| Weighted Avg Shares Out (Dil) | 13.38M | 13.38M | 13.38M |
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
Source: https://incomestatements.info
Category: Stock Reports